Y-Intercept (HK)’s Oric Pharmaceuticals ORIC Stock Holding History

Y-Intercept (HK)’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.46M	Buy	+108,320	New	+$1.35M	0.03%	792
2026 Q2	–	Sell	-111,992	Closed	-$1.42M	–	2047
2026 Q1	$1.42M	Sell	111,992 -229,431	-67%	-$2.6M	0.03%	890
2025 Q4	$2.79M	Buy	+341,423	New	+$3.93M	0.06%	459
2022 Q3	–	Sell	-10,828	Closed	-$49K	–	1194
2022 Q2	$49K	Buy	+10,828	New	+$43.2K	0.01%	753

Other funds holding ORIC

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Y-Intercept (HK)'s ORIC Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Oric Pharmaceuticals (ORIC) in Q3 2026: 108,320 shares worth $1.46M. The stake represents 0.03% of the portfolio and ranks #792 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in ORIC as recently as Q1 2026.

Y-Intercept (HK) first reported a position in ORIC in Q2 2022 and has held it in 4 quarters since. The position peaked at $2.79M in Q4 2025. 13 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

Y-Intercept (HK) held 108,320 shares of Oric Pharmaceuticals worth $1.46M as of Q3 2026.
Oric Pharmaceuticals was a new Y-Intercept (HK) position in Q3 2026.
Oric Pharmaceuticals made up 0.03% of Y-Intercept (HK)'s portfolio in Q3 2026, its #792 holding.
Y-Intercept (HK) first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
Y-Intercept (HK)'s Oric Pharmaceuticals position peaked at $2.79M in Q4 2025.
13 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.